Wednesday, October 09, 2024 7:41:54 AM
KZR...........................https://stockcharts.com/h-sc/ui?s=KZR&p=W&b=5&g=0&id=p86431144783
Recent KZR News
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 04/14/2026 10:01:13 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/07/2026 01:28:45 AM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 04/03/2026 08:58:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:49:16 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 03/30/2026 12:36:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 12:32:44 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:15:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 01:11:56 PM
- Enodia Therapeutics erweitert sein Sec61-Portfolio durch den Erwerb präklinischer Vermögenswerte von Kezar Life Sciences • Business Wire • 03/12/2026 01:00:00 PM
- Enodia Therapeutics renforce son portefeuille du Sec61 grâce à l'acquisition d'actifs précliniques auprès de Kezar Life Sciences • Business Wire • 03/12/2026 01:00:00 PM
- Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences • Business Wire • 03/12/2026 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/09/2026 07:39:13 PM
- Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis • Business Wire • 01/09/2026 11:01:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 06:33:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:21:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:07:21 PM
- Kezar Life Sciences Reports Third Quarter 2025 Financial Results • Business Wire • 11/12/2025 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 09:21:15 PM
- Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 • Business Wire • 11/07/2025 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2025 08:19:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2025 08:22:50 PM
- Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives • Business Wire • 10/16/2025 08:05:00 PM
- Kezar Life Sciences to Participate in Two Upcoming Investor Conferences • Business Wire • 08/28/2025 08:01:00 PM
